Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

The utility of urine-circulating miRNAs for detection of prostate cancer.

Stuopelyte K, Daniunaite K, Bakavicius A, Lazutka JR, Jankevicius F, Jarmalaite S.

Br J Cancer. 2016 Aug 4. doi: 10.1038/bjc.2016.233. [Epub ahead of print]

PMID:
27490805
2.

Detection of miRNAs in urine of prostate cancer patients.

Stuopelytė K, Daniūnaitė K, Jankevičius F, Jarmalaitė S.

Medicina (Kaunas). 2016;52(2):116-24. doi: 10.1016/j.medici.2016.02.007. Epub 2016 Mar 11.

3.

Frequent down-regulation of ABC transporter genes in prostate cancer.

Demidenko R, Razanauskas D, Daniunaite K, Lazutka JR, Jankevicius F, Jarmalaite S.

BMC Cancer. 2015 Oct 12;15:683. doi: 10.1186/s12885-015-1689-8.

4.

Epigenetic regulation of human adipose-derived stem cells differentiation.

Daniunaite K, Serenaite I, Misgirdaite R, Gordevicius J, Unguryte A, Fleury-Cappellesso S, Bernotiene E, Jarmalaite S.

Mol Cell Biochem. 2015 Dec;410(1-2):111-20. doi: 10.1007/s11010-015-2543-7. Epub 2015 Aug 26.

PMID:
26307369
5.

Correction: Analysis of Deregulated microRNAs and Their Target Genes in Gastric Cancer.

Juzėnas S, Saltenienė V, Kupcinskas J, Link A, Kiudelis G, Jonaitis L, Jarmalaite S, Kupcinskas L, Malfertheiner P, Skieceviciene J.

PLoS One. 2015 Aug 12;10(8):e0135762. doi: 10.1371/journal.pone.0135762. eCollection 2015. No abstract available.

6.

Analysis of Deregulated microRNAs and Their Target Genes in Gastric Cancer.

Juzėnas S, Saltenienė V, Kupcinskas J, Link A, Kiudelis G, Jonaitis L, Jarmalaite S, Kupcinskas L, Malfertheiner P, Skieceviciene J.

PLoS One. 2015 Jul 14;10(7):e0132327. doi: 10.1371/journal.pone.0132327. eCollection 2015. Erratum in: PLoS One. 2015;10(8):e0135762.

7.

Heterogeneity of DNA methylation in multifocal prostate cancer.

Serenaite I, Daniunaite K, Jankevicius F, Laurinavicius A, Petroska D, Lazutka JR, Jarmalaite S.

Virchows Arch. 2015 Jan;466(1):53-9. doi: 10.1007/s00428-014-1678-3. Epub 2014 Nov 5.

PMID:
25369892
8.

Prognostic value of O-6-methylguanine-DNA methyltransferase loss in salivary gland carcinomas.

Scesnaite A, Jarmalaite S, Mueller M, Agaimy A, Zenk J, Hartmann A, Iro H, Peters B, Schwarz S, Schneider-Stock R.

Head Neck. 2014 Sep;36(9):1258-67. doi: 10.1002/hed.23445. Epub 2013 Nov 27.

PMID:
25201059
9.

Prognostic value of RASSF1 promoter methylation in prostate cancer.

Daniunaite K, Jarmalaite S, Kalinauskaite N, Petroska D, Laurinavicius A, Lazutka JR, Jankevicius F.

J Urol. 2014 Dec;192(6):1849-55. doi: 10.1016/j.juro.2014.06.075. Epub 2014 Jun 26.

PMID:
24980613
10.

High-resolution melting-based quantitative analysis of RASSF1 methylation in breast cancer.

Stuopelytė K, Daniūnaitė K, Laurinavičienė A, Ostapenko V, Jarmalaitė S.

Medicina (Kaunas). 2013;49(2):78-83.

11.

Epigenetic markers of prostate cancer in plasma circulating DNA.

Cortese R, Kwan A, Lalonde E, Bryzgunova O, Bondar A, Wu Y, Gordevicius J, Park M, Oh G, Kaminsky Z, Tverkuviene J, Laurinavicius A, Jankevicius F, Sendorek DH, Haider S, Wang SC, Jarmalaite S, Laktionov P, Boutros PC, Petronis A.

Hum Mol Genet. 2012 Aug 15;21(16):3619-31. doi: 10.1093/hmg/dds192. Epub 2012 May 22.

12.

Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.

Sabaliauskaite R, Jarmalaite S, Petroska D, Dasevicius D, Laurinavicius A, Jankevicius F, Lazutka JR.

Genes Chromosomes Cancer. 2012 Aug;51(8):781-91. doi: 10.1002/gcc.21963. Epub 2012 Apr 16.

PMID:
22505341
13.

Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.

Laurinavicius A, Laurinaviciene A, Ostapenko V, Dasevicius D, Jarmalaite S, Lazutka J.

Diagn Pathol. 2012 Mar 16;7:27. doi: 10.1186/1746-1596-7-27.

14.

Similar DNA methylation pattern in lung tumours from smokers and never-smokers with second-hand tobacco smoke exposure.

Scesnaite A, Jarmalaite S, Mutanen P, Anttila S, Nyberg F, Benhamou S, Boffetta P, Husgafvel-Pursiainen K.

Mutagenesis. 2012 Jul;27(4):423-9. doi: 10.1093/mutage/ger092. Epub 2012 Jan 4.

15.
16.

Tumor suppressor gene ZAC/PLAGL1: altered expression and loss of the nonimprinted allele in pheochromocytomas.

Jarmalaite S, Laurinaviciene A, Tverkuviene J, Kalinauskaite N, Petroska D, Böhling T, Husgafvel-Pursiainen K.

Cancer Genet. 2011 Jul;204(7):398-404. doi: 10.1016/j.cancergen.2011.07.002.

PMID:
21872827
17.

Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer.

Daniūnaitė K, Berezniakovas A, Jankevičius F, Laurinavičius A, Lazutka JR, Jarmalaitė S.

Medicina (Kaunas). 2011;47(3):147-53. English, Lithuanian.

18.

Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study.

Jarmalaite S, Andrekute R, Scesnaite A, Suziedelis K, Husgafvel-Pursiainen K, Jankevicius F.

J Cancer Res Clin Oncol. 2010 Jun;136(6):847-54. doi: 10.1007/s00432-009-0725-y. Epub 2009 Nov 19.

PMID:
19924441
19.

Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.

Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, Husgafvel-Pursiainen K.

Oncology. 2008;75(3-4):145-51. doi: 10.1159/000158665. Epub 2008 Sep 29.

PMID:
18824877
20.

Preferential loss of the nonimprinted allele for the ZAC1 tumor suppressor gene in human capillary hemangioblastoma.

Lemeta S, Jarmalaite S, Pylkkänen L, Böhling T, Husgafvel-Pursiainen K.

J Neuropathol Exp Neurol. 2007 Sep;66(9):860-7.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk